Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Bevacizumab + Chemotherapy in MSS mCRC
NCT06415851Phase 2Not yet recruiting
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in metastatic colorectal cancer (mCRC). Primary endpoint: Progression-Free Survival at 100 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06415851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415851.